Table 5.
Participants’ demographic and clinical data.
| All PD patients (n = 40) | All HCs (n = 40) | All PD patients vs. all HCs | |
|---|---|---|---|
| Sociodemographic variables | |||
| Sex (F:M) | 15:25 | 15:25 | – |
| Age | 62.25 (9.27) | 61.87 (7.32) | 0.84a |
| Years of education | 12.23 (5.01) | 12.75 (4.62) | 0.63a |
| Clinical variables | |||
| Years since diagnosis | 5.65 (3.72) | – | – |
| UPDRS-III | 31.0 (12.54) | – | – |
| H&Y | 2.05 (0.29) | – | – |
| IFS battery | 19.56 (3.36) | 22.92 (2.67) | 0.07a |
| Barthel Index | 100 (0) | – | – |
| L&B | 8 (0) | – | – |
| MoCA | 24.75 (2.99) | 26.7 (1.63) | >0.01a |
| LED | 658.27 (375) | – | – |
Data presented as mean (SD); sex was self-reported.
PD Parkinson’s disease, HCs healthy controls, UPDRS-III Unified Parkinson’s Disease Rating Scale, part III, H&Y Hoehn & Yahr scale, IFS INECO Frontal Screening, L&B Lawton & Brody Index, MoCA Montreal Cognitive Assessment, LED Levodopa equivalent dose.
ap-values calculated using Mann–Whitney U tests.